2289.HK Charmacy (HKSE) up 23.90% to HK$7.31 on 23 Jan 2026: volume-led move
The 2289.HK stock jumped 23.90% to HK$7.31 intraday on 23 Jan 2026 on the Hong Kong Stock Exchange (HKSE). The price rise came with a volume spike — 1,000 shares vs average 441, a relative volume of 2.27, marking the stock among today’s high-volume movers. Traders are reacting to fresh buying interest; we track valuation, technicals, and Meyka AI model forecasts to explain the move and short-term outlook for Charmacy Pharmaceutical Co., Ltd.
Intraday move: 2289.HK stock leads high-volume movers
Charmacy Pharmaceutical Co., Ltd. (2289.HK) is an intraday leader on HKSE, trading at HK$7.31, up HK$1.41 (23.90%) from yesterday’s close of HK$5.90. Volume is 1,000 versus an average of 441, signaling outsized trader interest. The day range is tight at HK$7.28–HK$7.31, suggesting front-loaded buying at the open. This single claim: elevated volume plus a big percent move places 2289.HK on watch lists for momentum traders and liquidity screens.
Fundamentals and valuation for 2289.HK stock
Charmacy’s trailing metrics show a PE of 14.62, EPS HK$0.50, and market cap about HK$789,480,000.00. Price-to-book is 1.19 and price-to-sales is 0.17, below many healthcare peers. The company reports free cash flow yield of 38.95% and dividend per share HK$0.4371 (dividend yield ~6.69%). One claim: fundamentals show a value tilt but are offset by higher debt (debt-to-equity 1.78) and modest margins (net margin 1.14%).
Technical snapshot and short-term signals for 2289.HK stock
Technical indicators show a short-term bullish bias: RSI 60.49, ADX 38.74 (strong trend), MACD histogram positive. Price sits above the 50-day average (HK$6.26) and slightly above the 200-day average (HK$6.67). Bollinger upper band is HK$7.97, suggesting room to test highs. One claim: momentum and trend indicators support continuation while MFI at 100 flags short-term overbought conditions.
Meyka AI rates 2289.HK with a score out of 100 and model forecasts
Meyka AI rates 2289.HK with a score out of 100: 69.79 (Grade B, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects monthly HK$6.12, quarterly HK$5.01, and yearly HK$3.25. Compared with the current price HK$7.31, the model implies downside of -16.28% (monthly), -31.48% (quarterly), and -55.55% (yearly). Forecasts are model-based projections and not guarantees. For company info see Charmacy website and our coverage on Meyka stock page for 2289.HK.
Risks and opportunities affecting 2289.HK stock
One clear claim: upside is driven by value metrics, dividend yield 6.69%, and a B2B e-commerce channel, while risks include high leverage (debt-to-equity 1.78), long receivable days (107 days), and thin free float that can amplify moves. Regulatory risk in China’s pharmaceutical distribution sector and seasonality in inventory cycles add volatility. Sector context: healthcare peers trade at average PE near 29.68, so Charmacy appears cheaper on multiple ratios.
Trading strategy for high-volume movers: 2289.HK stock
For active traders watching high-volume movers the single claim is: use scaled entries and clear stops. Consider partial profit taking near resistance bands (Bollinger upper HK$7.97), and a short-term price target at HK$8.50 (implied upside 16.28%) with a conservative target at HK$6.50 (implied downside -11.08%). Keep position size small given on‑chain volume of 1,000 shares and MFI overbought readings.
Final Thoughts
Key takeaways on the 2289.HK stock intraday move: Charmacy surged to HK$7.31, rising 23.90% on a volume spike (1,000 vs avg 441), making it a top high-volume mover on HKSE today. Fundamentals show attractive value metrics—PE 14.62, price-to-book 1.19, and dividend yield 6.69%—but are tempered by high debt-to-equity 1.78 and stretched receivables days. Meyka AI’s model projects nearer-term levels of HK$6.12 (monthly) and HK$5.01 (quarterly), and a one-year projection of HK$3.25, implying downside vs current price; these are model outputs, not guarantees. Traders should treat today’s move as liquidity-driven and set tight risk controls: short-term target HK$8.50 (upside 16.28%) and conservative support near HK$6.50 (downside -11.08%). Meyka AI provides this AI-powered market analysis platform view to help interpret volume-led moves and frame risk-adjusted decisions.
FAQs
Why did the 2289.HK stock jump today
The intraday jump was driven by a volume surge (1,000 vs avg 441) and buying pressure at the open. Technical momentum (RSI 60.49, ADX 38.74) amplified the move. No single public catalyst was released; traders reacted to liquidity and valuation signals.
What are the valuation metrics for 2289.HK stock
Charmacy trades at PE 14.62, price-to-book 1.19, price-to-sales 0.17, and offers a dividend yield of about 6.69%. These metrics suggest value relative to many healthcare peers but reflect higher leverage.
What does Meyka AI forecast for 2289.HK stock
Meyka AI’s forecast model projects monthly HK$6.12, quarterly HK$5.01, and yearly HK$3.25. Models imply downside versus today’s price; forecasts are projections and not guarantees.
How should traders approach 2289.HK stock after the spike
Use scaled entries, tight stops, and profit targets. Short-term traders can target HK$8.50 with protective stops below HK$6.50. Size positions modestly given thin intraday volume.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
